In this National Emerging Special Pathogen Training and Education Center webinar attendees will discuss current evidence surrounding clinical trials for COVID-19 therapeutics including ACTT1, ACTT2, and ACTT3, and describe the FDA’s Coronavirus Treatment Acceleration Program (CTAP) when determining new treatments for COVID that are deemed safe and effective. Register Here